Andrew Advani

MD, FRCP, PhD, MBChB(Hons), BSc

Scientist, Keenan Research Centre for Biomedical Science

Biography

Dr. Andrew Advani is a Staff Endocrinologist and Associate Professor/Clinician Scientist at the Keenan Research Centre for Biomedical Science, St. Michael’s Hospital and Department of Medicine at University of Toronto. His research program is focused on the discovery and development of new treatments for diabetic kidney disease and related cardiovascular and kidney diseases.

Despite current treatments, people with diabetes continue to be affected by the long-term consequences of the disease. These long-term consequences include kidney disease, eye disease, nerve disease and heart disease. Kidney disease due to diabetes is the most common cause of kidney failure requiring treatment with dialysis or a kidney transplant and people with kidney disease are much more likely to die from heart disease. The Advani Lab is committed to conducting research on the causes of kidney disease in diabetes and on the links between kidney disease and heart disease. Through this research, Dr. Advani aims to develop new and better treatments for diabetes to reduce the burden of the condition on the millions of people affected.

Dr. Advani completed his medical training at the University of Edinburgh (UK) in 1996 and his PhD at Newcastle University (UK) in 2003. He was appointed on Staff at St. Michael’s Hospital in 2008. He is a Fellow of the Royal College of Physicians (UK). He has over 50 publications and has won awards from the British Hypertension Society, Royal College of Physicians (UK), Canadian Diabetes Association and Banting and Best Diabetes Centre. Research in the Advani Lab is supported by the Canadian Institutes of Health Research, Canadian Diabetes Association, Heart and Stroke Foundation of Canada and Kidney Foundation of Canada.

The Advani Lab is always interested in hearing from highly motivated and accomplished individuals interested in post-doctoral fellowships or graduate studentships.

Recent Publications

  1. Thieme, K, Majumder, S, Brijmohan, AS, Batchu, SN, Bowskill, BB, Alghamdi, TA et al.. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep. 2017;7 (1):3442. doi: 10.1038/s41598-017-03237-3. PubMed PMID:28611444 PubMed Central PMC5469816.
  2. Alghamdi, TA, Majumder, S, Thieme, K, Batchu, SN, White, KE, Liu, Y et al.. Janus Kinase 2 Regulates Transcription Factor EB Expression and Autophagy Completion in Glomerular Podocytes. J. Am. Soc. Nephrol. 2017; :. doi: 10.1681/ASN.2016111208. PubMed PMID:28424277 .
  3. Lytvyn, Y, Har, R, Locke, A, Lai, V, Fong, D, Advani, A et al.. Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. Diabetes. 2017;66 (7):1939-1949. doi: 10.2337/db17-0168. PubMed PMID:28408434 .
  4. Rajasekeran, H, Lytvyn, Y, Bozovic, A, Lovshin, JA, Diamandis, E, Cattran, D et al.. Urinary adenosine excretion in type 1 diabetes. Am. J. Physiol. Renal Physiol. 2017;313 (2):F184-F191. doi: 10.1152/ajprenal.00043.2017. PubMed PMID:28381459 .
  5. Majumder, S, Advani, A. VEGF and the diabetic kidney: More than too much of a good thing. J. Diabetes Complicat. 2017;31 (1):273-279. doi: 10.1016/j.jdiacomp.2016.10.020. PubMed PMID:27836681 .
  6. Markowitz, B, Parsons, JA, Advani, A. Diabetes in Emerging Adulthood: Transitions Lost in Translation. Can J Diabetes. 2017;41 (1):1-5. doi: 10.1016/j.jcjd.2016.06.004. PubMed PMID:27658766 .
  7. Marso, SP, Bain, SC, Consoli, A, Eliaschewitz, FG, Jódar, E, Leiter, LA et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 2016;375 (19):1834-1844. doi: 10.1056/NEJMoa1607141. PubMed PMID:27633186 .
  8. Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA et al.. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2016;375 (4):311-22. doi: 10.1056/NEJMoa1603827. PubMed PMID:27295427 PubMed Central PMC4985288.
  9. Batchu, SN, Brijmohan, AS, Advani, A. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin. Sci. 2016;130 (12):987-1003. doi: 10.1042/CS20160084. PubMed PMID:27154743 .
  10. Yu, CH, Guarna, G, Tsao, P, Jesuthasan, JR, Lau, AN, Siddiqi, FS et al.. Incentivizing health care behaviors in emerging adults: a systematic review. Patient Prefer Adherence. 2016;10 :371-81. doi: 10.2147/PPA.S102574. PubMed PMID:27069356 PubMed Central PMC4818043.
Search PubMed

Affiliations & Other Activities

  • Staff Endocrinologist/Clinician Scientist, Division of Endocrinology, St. Michael’s Hospital
  • Associate Professor/Clinician Scientist, Department of Medicine, University of Toronto
X